ema semaglutide reviewing data after reports of suicidal thoughts and thoughts of self-harm after taking GLP-1a EMA Identifies Rare Risk of

Semaglutide injection is Food and Drug Administration FDA-approved and has undergone rigorous clinical tests to ensure its safety and effectiveness

Theyre the flywheel starter: before momentum comes movement

If you see bubbles, tap the syringe gently and push them back into the vial, then redraw to the correct amount

TRIUMPH-4, a global, randomized study, evaluated retatrutides two highest doses, 9 mg and 12 mg, over a 68 week period

And it's also easy to forget that though a lot of people are using this for weight loss, most are using it for diabetes and may have other comorbid conditions that make them more susceptible to some of these rare side effects, Dr

While type 2 diabetes and obesity are the main conditions that GLP-1 agonists are used to treat, there is some evidence to suggest that they may also have additional health advantages aside from meaningful weight loss and metabolic health